SCHEDULE: Vanguard Group Reports 0% Stake in Corcept Therapeutics

The Vanguard Group has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Corcept Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 9 to its Schedule 13G for Corcept Therapeutics Inc. common stock.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Corcept Therapeutics Inc. securities.
• This change stems from an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• As a result of the realignment, certain subsidiaries or business divisions of Vanguard will now report beneficial ownership separately, and The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over these securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Corcept Therapeutics, as it primarily reflects an internal organizational and reporting change by The Vanguard Group rather than a direct investment or divestment decision related to Corcept's performance or prospects.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that such internal realignments by large institutional investors like The Vanguard Group are common and typically reflect internal operational or compliance adjustments rather than a change in investment thesis regarding the underlying company, Corcept Therapeutics. The shift to disaggregated reporting by subsidiaries is a procedural change in how beneficial ownership is disclosed, not necessarily a divestment of the entire Vanguard ecosystem's holdings.

Stakeholder Impact

• Shareholders: Existing shareholders of Corcept Therapeutics Inc. should be aware that The Vanguard Group, Inc. (the parent entity) no longer directly reports beneficial ownership, but its subsidiaries may still hold shares and report them separately. This is a reporting change, not necessarily a full divestment by all Vanguard-managed funds.
• Regulatory Authorities: The SEC is informed of the change in beneficial ownership reporting structure by a significant institutional investor.

Key Dates

Recommendation

This filing primarily details an internal organizational and reporting change by The Vanguard Group, not a fundamental shift in Corcept Therapeutics' business or prospects. As such, it provides no new information to warrant a change in investment recommendation for Corcept Therapeutics. Investors should continue to hold based on Corcept's operational performance and future outlook, which are not addressed in this filing.

Keywords

Corcept Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, SEC filing, common stock, ownership change